Protagonist Therapeutics (PTGX) – Research Analysts’ Weekly Ratings Changes

Posted by James Quigley on Nov 10th, 2026

A number of research firms have changed their ratings and price targets for Protagonist Therapeutics (NASDAQ: PTGX):

11/9/2026 – Protagonist Therapeutics had its “outperform” rating reaffirmed by Wedbush.
11/7/2026 – Protagonist Therapeutics was upgraded by Wall Street Zen from “buy” to “strong-buy”.
11/6/2026 – Protagonist Therapeutics had its price target raised by HC Wainwright from $170.00 to $221.00. They now have a “buy” rating on the stock.
11/4/2026 – Protagonist Therapeutics was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
11/3/2026 – Protagonist Therapeutics had its “buy” rating reaffirmed by UBS Group.
10/23/2026 – Protagonist Therapeutics was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
10/21/2026 – Protagonist Therapeutics had its price target raised by TD Cowen from $155.00 to $160.00. They now have a “buy” rating on the stock.
10/14/2026 – Protagonist Therapeutics was upgraded by Zacks Research from “hold” to “strong-buy”.
10/12/2026 – Protagonist Therapeutics is now covered by UBS Group. They set a “buy” rating and a $184.00 price target on the stock.
10/12/2026 – Protagonist Therapeutics was upgraded by UBS Group to “strong-buy”.
10/12/2026 – Protagonist Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $190.00 price target on the stock.
10/10/2026 – Protagonist Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
10/8/2026 – Protagonist Therapeutics was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.

Protagonist Therapeutics Trading Up 0.5%

Shares of PTGX traded up $0.69 during trading hours on Tuesday, reaching $136.59. 43,969 shares of the company traded hands, compared to its average volume of 711,569. Protagonist Therapeutics, Inc. has a 12-month low of $77.00 and a 12-month high of $160.81. The firm has a market cap of $8.84 billion, a price-to-earnings ratio of 28.94 and a beta of 1.21. The stock’s fifty day moving average price is $141.35 and its 200 day moving average price is $118.09.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $3.07 EPS for the quarter, beating the consensus estimate of $2.50 by $0.57. The firm had revenue of $274.41 million during the quarter, compared to analyst estimates of $238.49 million. Protagonist Therapeutics had a return on equity of 12.03% and a net margin of 29.40%. On average, research analysts forecast that Protagonist Therapeutics, Inc. will post 4.59 earnings per share for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In related news, CEO Dinesh V. Ph D. Patel sold 7,278 shares of Protagonist Therapeutics stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $144.10, for a total transaction of $1,048,759.80. Following the transaction, the chief executive officer owned 522,968 shares in the company, valued at approximately $75,359,688.80. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 58,629 shares of the stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $141.78, for a total transaction of $8,312,419.62. Following the completion of the sale, the chief financial officer directly owned 59,003 shares of the company’s stock, valued at approximately $8,365,445.34. This trade represents a 49.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 183,629 shares of company stock worth $26,552,987. 5.19% of the stock is owned by corporate insiders.

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets.

The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Founded in 2006 and based in Newark, California, Protagonist is led by co-founder and Chief Executive Officer Dinesh V.